Clinical trials: Social Fear
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Anxiety in Autistic Adults
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.
- Trial name
- NCT02008396
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Resilient Pharmaceuticals
Social Anxiety
Wiring Adolescents With Social Anxiety Via Behavioral Interventions
This study is a validation study to evaluate the acceptability, feasibility and impact of WASABI (Wiring Adolescents With Social Anxiety via Behavioral Interventions), a mobile application employing a closed-loop technology in…
- Trial name
- WASABI (NCT03990870)
- Testing
- dCBGT + WASABI, dCBGT Only
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Posit Science Corporation
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-1 (NCT04754802)
- Testing
- PH94B Nasal Spray
- Where
- 21 sites in United States
- Volunteers
- 224 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited
Social Anxiety Disorder (SAD)
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
This study is to compare two Virtual Reality (VR)-based interventions, BVR-100 and BES-100, for the treatment of Social Anxiety Disorder (SAD).
- Trial name
- BVR-100-102 (NCT06037668)
- Testing
- BVR-100, BES-100
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sumitomo Pharma America, Inc.
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-2 (NCT05011396)
- Testing
- PH94B Nasal Spray
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- VistaGen Therapeutics, Inc.